vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $120.9M, roughly 1.2× Sprout Social, Inc.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 12.9%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $9.9M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 11.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.
ADMA vs SPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $120.9M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | 77.6% |
| Operating Margin | 45.1% | -9.0% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 12.9% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $120.9M | ||
| Q3 25 | $134.2M | $115.6M | ||
| Q2 25 | $122.0M | $111.8M | ||
| Q1 25 | $114.8M | $109.3M | ||
| Q4 24 | $117.5M | $107.1M | ||
| Q3 24 | $119.8M | $102.6M | ||
| Q2 24 | $107.2M | $99.4M | ||
| Q1 24 | $81.9M | $96.8M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-9.4M | ||
| Q2 25 | $34.2M | $-12.0M | ||
| Q1 25 | $26.9M | $-11.2M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $-17.1M | ||
| Q2 24 | $32.1M | $-16.9M | ||
| Q1 24 | $17.8M | $-13.6M |
| Q4 25 | 63.8% | 77.6% | ||
| Q3 25 | 56.3% | 77.7% | ||
| Q2 25 | 55.1% | 77.7% | ||
| Q1 25 | 53.2% | 77.3% | ||
| Q4 24 | 53.9% | 78.1% | ||
| Q3 24 | 49.8% | 77.4% | ||
| Q2 24 | 53.6% | 77.5% | ||
| Q1 24 | 47.8% | 76.8% |
| Q4 25 | 45.1% | -9.0% | ||
| Q3 25 | 38.0% | -7.9% | ||
| Q2 25 | 35.1% | -11.0% | ||
| Q1 25 | 30.4% | -10.2% | ||
| Q4 24 | 32.6% | -12.8% | ||
| Q3 24 | 33.1% | -16.4% | ||
| Q2 24 | 36.6% | -16.6% | ||
| Q1 24 | 26.7% | -13.7% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -8.1% | ||
| Q2 25 | 28.1% | -10.7% | ||
| Q1 25 | 23.4% | -10.3% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | -16.6% | ||
| Q2 24 | 29.9% | -17.0% | ||
| Q1 24 | 21.7% | -14.0% |
| Q4 25 | $0.20 | $-0.18 | ||
| Q3 25 | $0.15 | $-0.16 | ||
| Q2 25 | $0.14 | $-0.21 | ||
| Q1 25 | $0.11 | $-0.19 | ||
| Q4 24 | $0.45 | $-0.25 | ||
| Q3 24 | $0.15 | $-0.30 | ||
| Q2 24 | $0.13 | $-0.30 | ||
| Q1 24 | $0.08 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $95.3M |
| Total DebtLower is stronger | $72.1M | $40.0M |
| Stockholders' EquityBook value | $477.3M | $203.4M |
| Total Assets | $624.2M | $523.1M |
| Debt / EquityLower = less leverage | 0.15× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $95.3M | ||
| Q3 25 | $61.4M | $90.6M | ||
| Q2 25 | $90.3M | $101.5M | ||
| Q1 25 | $71.6M | $100.9M | ||
| Q4 24 | $103.1M | $86.4M | ||
| Q3 24 | $86.7M | $82.9M | ||
| Q2 24 | $88.2M | $80.9M | ||
| Q1 24 | $45.3M | $69.2M |
| Q4 25 | $72.1M | $40.0M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $25.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $203.4M | ||
| Q3 25 | $431.2M | $194.1M | ||
| Q2 25 | $398.3M | $184.6M | ||
| Q1 25 | $373.4M | $175.3M | ||
| Q4 24 | $349.0M | $166.6M | ||
| Q3 24 | $231.9M | $158.1M | ||
| Q2 24 | $188.3M | $152.1M | ||
| Q1 24 | $153.7M | $147.3M |
| Q4 25 | $624.2M | $523.1M | ||
| Q3 25 | $568.7M | $481.4M | ||
| Q2 25 | $558.4M | $422.9M | ||
| Q1 25 | $510.6M | $424.7M | ||
| Q4 24 | $488.7M | $428.3M | ||
| Q3 24 | $390.6M | $388.8M | ||
| Q2 24 | $376.4M | $393.6M | ||
| Q1 24 | $350.9M | $389.9M |
| Q4 25 | 0.15× | 0.20× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $10.9M |
| Free Cash FlowOCF − Capex | $34.6M | $9.9M |
| FCF MarginFCF / Revenue | 24.8% | 8.2% |
| Capex IntensityCapex / Revenue | 0.8% | 0.9% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $39.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $10.9M | ||
| Q3 25 | $13.3M | $9.3M | ||
| Q2 25 | $21.1M | $5.1M | ||
| Q1 25 | $-19.7M | $18.1M | ||
| Q4 24 | $50.2M | $4.1M | ||
| Q3 24 | $25.0M | $9.0M | ||
| Q2 24 | $45.6M | $2.1M | ||
| Q1 24 | $-2.2M | $11.2M |
| Q4 25 | $34.6M | $9.9M | ||
| Q3 25 | $-1.1M | $8.5M | ||
| Q2 25 | $18.7M | $4.2M | ||
| Q1 25 | $-24.4M | $16.7M | ||
| Q4 24 | $47.5M | $3.3M | ||
| Q3 24 | $24.0M | $8.5M | ||
| Q2 24 | $43.6M | $1.6M | ||
| Q1 24 | $-4.6M | $10.1M |
| Q4 25 | 24.8% | 8.2% | ||
| Q3 25 | -0.8% | 7.4% | ||
| Q2 25 | 15.3% | 3.7% | ||
| Q1 25 | -21.2% | 15.3% | ||
| Q4 24 | 40.4% | 3.0% | ||
| Q3 24 | 20.0% | 8.3% | ||
| Q2 24 | 40.7% | 1.6% | ||
| Q1 24 | -5.6% | 10.4% |
| Q4 25 | 0.8% | 0.9% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 0.8% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | 2.3% | 0.8% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.5% | ||
| Q1 24 | 2.9% | 1.1% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SPT
Segment breakdown not available.
